Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy
- Registration Number
- NCT03906058
- Lead Sponsor
- Sun Yat-sen University
- Brief Summary
The purpose of this single arm, phase Ⅱ clinical trial is to evaluate the efficacy and safety of Anlotinib Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma after failure of no less than second-line chemotherapy or targeted therapy
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 39
Inclusion Criteria
- biopsy proved nasopharyngeal carcinoma;
- stage IVB according to American Joint Committee on Cancer(AJCC) edition VIII, or recurrent disease after chemotherapy and/or radiotherapy;
- 18 years or older; without other malignancy;
- proper functioning of the major organs.
Exclusion Criteria
- allergic to anlotinib;
- female within gestation period or lactation;
- patients received drug of other clinical trial within 4 weeks.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Anlotinib Anlotinib -
- Primary Outcome Measures
Name Time Method disease control rate 30 months disease control rate
- Secondary Outcome Measures
Name Time Method duration of response 30 months duration of response
overall survival 30 months overall survival
progression-free survival 30 months progression-free survival
overall response rate 30 months overall response rate
Trial Locations
- Locations (1)
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
🇨🇳Guangzhou, Guangdong, China